Product Pipeline
- Alimera Sciences, Inc. owns worldwide rights to ILUVIEN® for DME and rights for YUTIQ® for non-infectious posterior uveitis in the EMEA with a royalty payable to EyePoint.
- Excludes China, Hong Kong, Taiwan and Macau
Please complete the form below to receive information on the availability of Dexycu.
DEXYCU Physician Perspective
DEXYCU Patient Perspective
DEXYCU® (dexamethasone intraocular suspension) 9% Injection Video
YUTIQ Physician Perspective
Yutiq® Shorter Duration for Posterior Uveitis
Potential Indication: posterior segment uveitis
EyePoint is currently developing a shorter-duration sustained-release fluocinolone acetonide product in the proven DurasertTM Technology.
DurasertTM Bioerodible TKI
Potential Indication: Wet AMD
EyePoint is focused on developing a sustained-release bioerodible device containing a tyrosine kinase inhibitor (TKI) to assess its potential to treat wet AMD. In-vitro release profiles have been assessed for several TKIs.